CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
CARGO Therapeutics, Inc. (CRGX)
Company Research
Source: Yahoo! Finance
SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023. To date, 20 sites have been initiated and are enrolling for the potentially pivotal Phase 2 clinical study, FIRCE-1. The Phase 2 trial (NCT05972720) is an open-label, multicenter Phase 2 clinical study evaluating the efficacy and safety of firicabtagene autoleucel (firi-cel) (CRG-022) in patients with relapse or refractory (R/R) large B-cell lymphoma (LBCL) whose disease has progressed after CD19-directed CAR T-cell therapy, an area of high unmet need. Interim results are anticipated in the first half of 2025. “2023 was a transformative year for CARGO as we built our leadership team and attracted top talent, initiated FIRCE-1, a potentially
Show less
Read more
Impact Snapshot
Event Time:
CRGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRGX alerts
High impacting CARGO Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CRGX
News
- Is There An Opportunity With CARGO Therapeutics, Inc.'s (NASDAQ:CRGX) 21% Undervaluation? [Yahoo! Finance]Yahoo! Finance
- CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors [Yahoo! Finance]Yahoo! Finance
- CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of DirectorsGlobeNewswire
- CARGO Therapeutics, Inc. (NASDAQ: CRGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $28.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
CRGX
Earnings
- 3/21/24 - Beat
CRGX
Sec Filings
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- 4/17/24 - Form 4
- CRGX's page on the SEC website